This proposal is the logical continuation of an exploratory collaborative grant (R21,Herold - von Herrath) focused to develop novel combinatorial approaches of recent-onset type 1 diabetes (T1D). Forthcoming results in two independent diabetes models (NOD and RIP-LCMV) have established the concept that, in order to achieve antigen-specific tolerance, combination of immunization with islet antigens and systemically acting immune modulators can exhibit strong synergy and be clinically beneficial for the following reasons: First, reversion of hyperglycemia can occur at lower dosages of the systemically acting immune modulator, in our case anti-CD3 Fab'2. Second, mechanistically, the induction of Tregs specific for islet antigens that can mediate long-term tolerance and bystander suppression is enhanced. This project seeks to deepen our mechanistic insight, and, in close collaboration with projects 2 and 3, address crucial issues that should facilitate translation of combinatorial therapy in recent-onset T1D to the clinic. Wewill answer the following questions: 1. Which is the optimal combinatorial therapeutic regimen in recent-onset T1D in vivo? Current data indicate that oral or nasal administration of insulin peptides bears most promise. In order to optimally tie into current choices in drug development, we will define the best candidate. In addition we will explore combination of antigen-specific therapy with GLP-1 agonists and gastrin to regenerate beta cells. 2. Which precise functions define the action of the islet antigen induced Tregs in vivo? Current findings show that long-term tolerance after anti-CD3 and antigen administration is, to a large part, due to induction of potent islet antigen-specific regulatory T cells (Tregs) that can transfer tolerance to recipients with recent-onset T1D. Their precise mechanism of action will be defined using novel technology and reagents recently acquired, RNAi and ins-TcR transgenic mice. 3. Which are optimal in vitro assays to monitor Tregs and antigen-sepcific tolerance in vivo? We will establish asays that reflect and predict the clinical out come on a per-animal basis. These assays should provide strong guidance to the goals of the clinical project (#3, Herold).

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK078013-05S1
Application #
8304518
Study Section
Special Emphasis Panel (ZAI1-MP-I (M1))
Program Officer
Spain, Lisa M
Project Start
2006-09-20
Project End
2012-06-30
Budget Start
2010-08-01
Budget End
2012-06-30
Support Year
5
Fiscal Year
2011
Total Cost
$486,604
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Van Belle, Tom L; Pagni, Philippe P; Liao, Jeanette et al. (2014) Beta-cell specific production of IL6 in conjunction with a mainly intracellular but not mainly surface viral protein causes diabetes. J Autoimmun 55:24-32
Sarikonda, Ghanashyam; Fousteri, Georgia; Sachithanantham, Sowbarnika et al. (2014) BDC12-4.1 T-cell receptor transgenic insulin-specific CD4 T cells are resistant to in vitro differentiation into functional Foxp3+ T regulatory cells. PLoS One 9:e112242
Pagni, Philippe P; Bresson, Damien; Rodriguez-Calvo, Teresa et al. (2014) Combination therapy with an anti-IL-1? antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes 63:2015-25
Boettler, Tobias; Pagni, Philippe P; Jaffe, Rachel et al. (2013) The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. J Autoimmun 44:40-8
van Belle, Tom L; Coppieters, Ken T; von Herrath, Matthias G (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91:79-118
Bresson, Damien; von Herrath, Matthias (2011) Humanizing animal models: a key to autoimmune diabetes treatment. Sci Transl Med 3:68ps4
Bresson, Damien; Fousteri, Georgia; Manenkova, Yulia et al. (2011) Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J Autoimmun 37:342-51
Van Belle, Tom L; Esplugues, Enric; Liao, Jeanette et al. (2011) Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model. J Immunol 187:2915-22
Boettler, Tobias; von Herrath, Matthias (2011) Protection against or triggering of Type 1 diabetes? Different roles for viral infections. Expert Rev Clin Immunol 7:45-53
Martinic, Marianne M; Huber, Christoph; Coppieters, Ken et al. (2010) Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis. J Autoimmun 35:404-13

Showing the most recent 10 out of 12 publications